JAMA[journal] 检索结果

登陆

当前位置: 首页 >> 检索结果

结果排序

文献格式

出版时间

出版类型

出版语言

共有 83980 条符合本次的查询结果，用时 2.3160939 秒

61. Research Limits on Knowledge of Benefit or Harm of Cannabis and Cannabinoids Use-Reply.

作者: Michael Hsu.;Mark S Gold.;Kevin P Hill.
来源: JAMA. 2026年

62. Lead-Attributable Cardiovascular Disease Burden: Global Burden of Disease Study 2023.

作者: .;Jeffrey D Stanaway.;Sandra Spearman.;Nicole K DeCleene.;Vanessa Garcia.;Laura Lara-Castor.;Stephen S Lim.;Christopher J L Murray.;Gregory A Roth.;Matthew A Seymour.;Benjamin Stark.;Michael Brauer.
来源: JAMA. 2026年

Despite declines, lead exposure remains a major risk factor for cardiovascular disease (CVD) mortality. Quantifying the direct effects of cumulative bone lead exposure on CVD is essential to guide prevention and policy.

63. Research Limits on Knowledge of Benefit or Harm of Cannabis and Cannabinoids Use.

作者: Jamie Corroon.;Igor Grant.
来源: JAMA. 2026年

64. Management of Acute Coronary Syndrome.

作者: Adam S Vohra.;Jason T Alexander.;Atman P Shah.
来源: JAMA. 2026年

65. Research Limits on Knowledge of Benefit or Harm of Cannabis and Cannabinoids Use.

作者: Shannon C Miller.;Marissa D Sbrilli.;Jag H Khalsa.
来源: JAMA. 2026年

66. Breast Density Masking and the Need for Precision Screening.

作者: Danielle B Holt.
来源: JAMA. 2026年

67. Lipid Lowering in 2026: Still Asking When, in Whom, and How.

作者: Philip Greenland.;Donald M Lloyd-Jones.
来源: JAMA. 2026年

68. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Research Summary.

来源: JAMA. 2026年e263429页

69. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.

作者: Nicholas A Marston.;Erin A Bohula.;Ajay K Bhatia.;Gaetano M De Ferrari.;Lawrence A Leiter.;Jose C Nicolau.;Jeong-Gun Park.;Sabina A Murphy.;Emileigh Walsh.;Lyrica Liu.;Subodh Verma.;Naveed Sattar.;Stephen J Nicholls.;Jose Lopez-Sendon.;Ioanna Gouni-Berthold.;Lale Tokgozoglu.;Ron Blankstein.;Marcoli Cyrille.;Gabriel Paiva da Silva Lima.;Robert P Giugliano.;Marc S Sabatine.; .
来源: JAMA. 2026年

Intensive lowering of low-density lipoprotein cholesterol (LDL-C) levels with PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors for cardiovascular event reduction has largely been reserved for patients with significant atherosclerosis.